Premium
The feasibility of using concentrates containing factor IX for continuous infusion
Author(s) -
SCHULMAN SAM,
GITEL SANFORD,
ZIVELIN ARIELA,
KATSAROU OLGA,
MANDALAKI TITIKA,
VARON DAVID,
MARTINOWITZ URI
Publication year - 1995
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.1995.tb00048.x
Subject(s) - factor ix , medicine , prothrombin complex concentrate , continuous infusion , chromatography , surgery , chemistry , warfarin , atrial fibrillation
Summary We have investigated the feasibility of continuous infusion of undiluted factor IX (F IX) over several days using minipumps. The stabilities of seven different reconstituted F IX products were substantially better than those declared by the manufacturers. Several concentrates maintained factor activities 80% of baseline for the entire period of 4 weeks at 4‐8d̀C as did one product at 20–23d̀A. At 37d̀C the latter concentrate was stable for at least 1 week. The stability seemed to correlate with the purity of the product. Analysis of two prothrombin comples concentrates by gel electrophoresis demonstrated degradation of prothrombin to prethrombin‐1 and fragment 1 at 37d̀C and in one of the concentrates also at 20–23d̀C. In two F IX concentrates the corresponding analysis did not reveal any degradation. Four patients were treated with continuous infusion with a pure F IX concentrate (Mononine™, Armour) after surgery or for serious haemorrhage (two each) with good haemostatic effect, an initial progressive decrease of the F IX clearance, and no side‐effects. Continuous infusion with F IX, using a minipump and undiluted reconstituted factor, is therefore feasible and effective, and can be conveniently prepared for several days at a time. Pure F IX products are more stable and probably safer for this purpose.